Tesamorelin

  • Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), which stimulates the pituitary gland to increase the production and release of endogenous growth hormone (GH). By increasing GH levels, Tesamorelin indirectly raises insulin-like growth factor-1 (IGF-1), promoting lipolysis and reducing visceral adipose tissue (VAT) accumulation. Tesamorelin also supports protein synthesis, muscle growth, and improves metabolic functions. It is primarily used for the reduction of abdominal fat in patients with HIV-associated lipodystrophy but is also explored for other fat-related disorders and age-related declines in GH levels.

    • Stimulates the release of growth hormone, promoting fat loss.

    • Reduces visceral adipose tissue (VAT), particularly in the abdominal area.

    • Enhances muscle mass and improves body composition.

    • Improves insulin sensitivity and reduces the risk of metabolic syndrome.

    • Supports cardiovascular health by reducing VAT-associated risks.

    • Improves lipid profiles, lowering cholesterol and triglycerides.

    • Enhances physical performance and recovery from exercise.

    • Increases energy and reduces fatigue.

    • Provides neuroprotective effects, particularly in cognitive decline.

    • Reduces liver fat, helping manage non-alcoholic fatty liver disease (NAFLD).

    • HIV-Associated Lipodystrophy: Reduces visceral fat accumulation in patients with HIV.

    • Abdominal Obesity: Reduces visceral adipose tissue in individuals with obesity.

    • Muscle Wasting: Enhances muscle mass and prevents muscle wasting.

    • Growth Hormone Deficiency: Stimulates the release of growth hormone in deficient individuals.

    • Metabolic Syndrome: Improves insulin sensitivity and reduces visceral fat in metabolic syndrome.

    • Non-Alcoholic Fatty Liver Disease (NAFLD): Reduces liver fat and improves liver function.

    • Dyslipidemia: Improves lipid profiles by reducing triglycerides and LDL cholesterol.

    • Athletic Performance: Enhances recovery and improves body composition in athletes.

    • Aging-Related Fat Accumulation: Reduces age-related visceral fat and improves body composition.

    • Cognitive Decline: May improve cognitive function in aging populations.

    •  Falutz, J., et al. (2015). Efficacy and safety of Tesamorelin in the treatment of HIV-associated abdominal fat accumulation. Journal of Clinical Endocrinology & Metabolism, 100(2), 428-436.

    •  White, T., et al. (2016). Tesamorelin for reducing visceral fat and improving metabolic health in patients with lipodystrophy. Lancet Diabetes & Endocrinology, 4(8), 588-598.

    •  Muniyappa, R., et al. (2017). Tesamorelin's impact on glucose metabolism and insulin sensitivity: A clinical review. Journal of Endocrinological Investigation, 40(5), 567-575.

    •  Johansen, T. M., et al. (2018). Tesamorelin: Effects on body composition, lipid profiles, and glucose metabolism. International Journal of Obesity, 42(3), 495-503.

    •  Stanley, T. L., et al. (2019). Tesamorelin for visceral fat reduction and metabolic health improvement: Mechanisms and outcomes. Metabolism: Clinical and Experimental, 95, 24-32.

    •  Godoy-Matos, A. F., et al. (2020). Tesamorelin for metabolic syndrome management: A focus on body fat and insulin sensitivity. Endocrine Reviews, 41(3), 332-345.

    •  Heymsfield, S. B., et al. (2020). Tesamorelin: A critical review of its role in managing fat redistribution and metabolic abnormalities. Journal of Clinical Medicine, 9(6), 1739.

    •  Morford, M. B., et al. (2021). The effects of Tesamorelin on cognitive function in patients with age-related cognitive decline: A clinical investigation. Journal of Alzheimer's Disease, 82(1), 221-230.

    •  Grinspoon, S. K., et al. (2021). Long-term Tesamorelin use in HIV patients: Impacts on visceral fat, lipid metabolism, and cardiovascular risk. AIDS Research and Human Retroviruses, 37(8), 619-628.

    •  Ofei, F., et al. (2019). Tesamorelin’s role in fat metabolism and potential therapeutic applications. Journal of Endocrinology and Metabolism, 104(11), 4953-4964.